Nubeqa Now Indicated for Metastatic Hormone-Sensitive Prostate Cancer

Web Exclusives - FDA Approvals

On August 5, 2022, the FDA accelerated the approval of darolutamide (Nubeqa; Bayer Healthcare), an androgen receptor inhibitor, in combination with docetaxel, for the treatment of metastatic hormone-sensitive prostate cancer in adults.

Darolutamide was previously approved for nonmetastatic castration-resistant prostate cancer.

The approval of this new indication was based on results of the randomized, multicenter, double-blind, placebo-controlled ARASENS phase 3 clinical trial of 1306 patients with metastatic hormone-sensitive prostate cancer. The patients received 600 mg of darolutamide orally twice daily plus 75 mg/m2 of docetaxel intravenously every 3 weeks for up to 6 cycles or docetaxel plus placebo.

The main end point was overall survival (OS); the secondary end point was time to pain progression. The median OS was not reached in the darolutamide arm versus 48.9 months (95% confidence interval [CI], 44.4-not reached) in the placebo arm (95% CI, 0.57-0.80; P <.0001).

Related Items
Imfinzi Receives New FDA Indication for Advanced or Metastatic Biliary Tract Cancer
Web Exclusives published on December 7, 2022 in FDA Approvals
Retevmo Receives New FDA Indication for Advanced Solid Tumors with RET Fusion
Web Exclusives published on November 30, 2022 in FDA Approvals
Imbruvica Now Also Indicated for Children with Chronic Graft-versus-Host Disease
Web Exclusives published on November 17, 2022 in FDA Approvals
Pemazyre Receives New Indication for FGFR1-­Positive Myeloid/Lymphoid Neoplasms
Web Exclusives published on November 17, 2022 in FDA Approvals
Vegzelma a New Biosimilar FDA Approved for the Treatment of 6 Types of Cancer
Web Exclusives published on October 31, 2022 in FDA Approvals
Last modified: December 20, 2022
Copyright © The Lynx Group, LLC. All rights reserved.